Clinical Trial Detail

NCT ID NCT02210117
Title Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

clear cell renal cell carcinoma

Therapies

Nivolumab

Bevacizumab + Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.